AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6486112 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast containing less than 15 g fat
Number of subjects: 15
Study 6486112 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast totally free of fat
Number of subjects: 15
Study 6486112 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of C‐terminal octapeptide of cholecystokinin
Number of subjects: 15
Study 31427339 — intervention group
Group type: EXPERIMENTAL
Intervention: IPCAS model of care including a structured review using a checklist; a self-management programme; enhanced communication pathways between primary care and specialist services; and direct point of contact for patients.
Number of subjects: 920
Study 31427339 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 920
Study 31427339 — intervention group
Group type: EXPERIMENTAL
Intervention: IPCAS model of care
Number of subjects: 920
Study 29326097 — intervention group
Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer
Number of subjects: 101
Study 26857421 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care with additional low dose chest CT
Number of subjects: 1724
Study 26857421 — intervention group
Group type: COMPARATOR
Intervention: Routine care including a chest x-ray
Number of subjects: 1724
Study 25127679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical tests (FITs), 3 tests (1/year for 3 years), cutoff ≥10 μg hemoglobin/g feces
Number of subjects: 1918
Study 25127679 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy, single examination
Number of subjects: 1918
Study 22322165 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 73
Study 22322165 — intervention group
Group type: COMPARATOR
Intervention: Control group (fellow-eye)
Number of subjects: 73
Study 21144937 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamer-Irrigator-Aspirator (RIA)
Number of subjects: 20
Study 21144937 — intervention group
Group type: COMPARATOR
Intervention: Conventional reamer
Number of subjects: 20
Study 18061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and visualization therapy (RVT) for 24 consecutive days
Number of subjects: 34
Study 18061756 — intervention group
Group type: COMPARATOR
Intervention: Control group (radiotherapy only)
Number of subjects: 34
Study 10665518 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% b.i.d.
Number of subjects: 0
Study 10665518 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% t.i.d.
Number of subjects: 0
Study 10665518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2.0% t.i.d.
Number of subjects: 0
Study 9487345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffumal‐24 (once daily at 20.00 hours)
Number of subjects: 12
Study 9487345 — intervention group
Group type: COMPARATOR
Intervention: Theo‐Dur (twice daily at 08.00 and 20.00 hours)
Number of subjects: 12
Study 9487345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8149942 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin (700 mg)
Number of subjects: 7
Study 8149942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with calcium carbonate (700 mg)
Number of subjects: 7
Study 8149942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with caffeine (700 mg)
Number of subjects: 7
Study 3749962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewing skills training based on the Developmental Helping Model (10-week course)
Number of subjects: 32
Study 3749962 — intervention group
Group type: COMPARATOR
Intervention: Traditionally focused training (control group)
Number of subjects: 32
Study 29519353 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (cyclical 20 mg/kg for 2 weeks every 12 weeks)
Number of subjects: 74
Study 29519353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29519353 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 74
Study 27801892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum 1714
Number of subjects: 22
Study 24714816 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (circuit with six stations, 3 days per week for 12 weeks)
Number of subjects: 40
Study 24714816 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 22112598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole + Nevirapine
Number of subjects: 0
Study 22112598 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole + Placebo
Number of subjects: 0
Study 20147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (fair or poor)
Number of subjects: 1199
Study 20147671 — intervention group
Group type: COMPARATOR
Intervention: Clinical history of myocardial infarction
Number of subjects: 1199
Study 20147671 — intervention group
Group type: COMPARATOR
Intervention: Insulin use
Number of subjects: 1199
Study 20147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-high school education
Number of subjects: 1199
Study 20147671 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan Neuropathy Screening Instrument scores, regular exercise, and employment
Number of subjects: 1199
Study 18249292 — intervention group
Group type: EXPERIMENTAL
Intervention: Eruption guidance appliance
Number of subjects: 167
Study 18249292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study 16181528 — intervention group
Group type: EXPERIMENTAL
Intervention: ZYTF combined with acupuncture and massotherapy
Number of subjects: 118
Study 16181528 — intervention group
Group type: COMPARATOR
Intervention: Simple Western medicine
Number of subjects: 118
Study 14616429 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (6 mg) alone
Number of subjects: 12
Study 14616429 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg) with caffeine (3 x 200 mg)
Number of subjects: 12
Study 10858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 80
Study 10858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 80
Study 10858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 80
Study 10858839 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 80
Study 9282610 — intervention group
Group type: EXPERIMENTAL
Intervention: SL Nifedipine 10 mg
Number of subjects: 102
Study 9282610 — intervention group
Group type: EXPERIMENTAL
Intervention: SL Captopril 25 mg
Number of subjects: 102
Study 9282610 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Metoprolol 15 mg
Number of subjects: 102
Study 9282610 — intervention group
Group type: EXPERIMENTAL
Intervention: SL Nifedipine + IV Metoprolol
Number of subjects: 102
Study 1658591 — intervention group
Group type: EXPERIMENTAL
Intervention: LAK cells injected i.a on days 10, 14, and 21 after operation with IL-2 injections during 3 weeks.
Number of subjects: 30
Study 1658591 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin treatment only (Control group).
Number of subjects: 30
Study 31170947 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT-Ai + TAU
Number of subjects: 53
Study 31170947 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 53
Study 28691508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal 15-week intervention programme (INT)
Number of subjects: 447
Study 28691508 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 447
Study 26446072 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt wean with HFNC
Number of subjects: 60
Study 26446072 — intervention group
Group type: COMPARATOR
Intervention: Abrupt wean without HFNC
Number of subjects: 60
Study 26446072 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual wean with HFNC
Number of subjects: 60
Study 26446072 — intervention group
Group type: COMPARATOR
Intervention: Gradual wean without HFNC
Number of subjects: 60
Study 23566246 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A)
Number of subjects: 68
Study 23566246 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) treated according to current recommendations without statin therapy
Number of subjects: 68
Study 21750010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chignon ankle-foot orthosis
Number of subjects: 28
Study 21750010 — intervention group
Group type: COMPARATOR
Intervention: Standard ankle-foot orthosis
Number of subjects: 28
Study 19645975 — intervention group
Group type: EXPERIMENTAL
Intervention: Berci-Kaplan Video Laryngoscope (VL)
Number of subjects: 60
Study 19645975 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 60
Study 18830045 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 treatment
Number of subjects: 0
Study 18830045 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytonadione (Vitamin K1) and menaquinone (Vitamin K2)
Number of subjects: 0
Study 16050219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound method for imaging the growth plate
Number of subjects: 269
Study 16050219 — intervention group
Group type: COMPARATOR
Intervention: X-ray method for imaging the growth plate
Number of subjects: 269
Study 11826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol mixture
Number of subjects: 1277
Study 11826229 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 1277
Study 11826229 — intervention group
Group type: COMPARATOR
Intervention: Control chewing gum
Number of subjects: 1277
Study 11826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum
Number of subjects: 1277
Study 11826229 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 1277
Study 10047932 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release carbidopa/levodopa (Sinemet, IR-CL)
Number of subjects: 52
Study 10047932 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa (Sinemet CR, CR-CL)
Number of subjects: 52
Study 8559497 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo treatment
Number of subjects: 17
Study 8559497 — intervention group
Group type: COMPARATOR
Intervention: Control (no rHuEpo treatment)
Number of subjects: 17
Study 2044646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitosterol (3.6 mumol/min)
Number of subjects: 0
Study 2044646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol (3.6 mumol/min)
Number of subjects: 0
Study 2044646 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 0
Study 7140397 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 13
Study 31746260 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch/gluten-based meals with soybean oil
Number of subjects: 8
Study 31746260 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch/gluten-based meals with palm oil
Number of subjects: 8
Study 30860474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5) add-on therapy for 24 weeks with entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Number of subjects: 45
Study 30860474 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Number of subjects: 45
Study 28745096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Feedback Intervention
Number of subjects: 0
Study 28745096 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 0
Study 26542476 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulation of the ear with ear protectors (Arton 2200)
Number of subjects: 31
Study 26542476 — intervention group
Group type: COMPARATOR
Intervention: No insulation of the ear
Number of subjects: 31
Study 23388507 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0-10 ng ml(‐1)) and sevoflurane (0.3-3.4 vol.%)
Number of subjects: 65
Study 21499755 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 280
Study 21499755 — intervention group
Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 280
Study 19515642 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR with silastic intubation
Number of subjects: 100
Study 19515642 — intervention group
Group type: COMPARATOR
Intervention: DCR without silastic intubation
Number of subjects: 100
Study 17545416 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior mini‐incision total hip arthroplasty (10 +/- 2 cm)
Number of subjects: 60
Study 17545416 — intervention group
Group type: COMPARATOR
Intervention: Conventional total hip arthroplasty (long incision, 20 +/- 2 cm)
Number of subjects: 60
Study 15552353 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition priming task (perceptual identification)
Number of subjects: 0
Study 15552353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mere exposure tasks (affective liking or preference judgment)
Number of subjects: 0
Study 15552353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 11903835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 0.2 mg/kg four times a day for 7 days
Number of subjects: 16
Study 11903835 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 16
Study 11903835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 16
Study 11903835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9272792 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for moderate pain
Number of subjects: 1080
Study 9272792 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for severe pain
Number of subjects: 1080
Study 7931432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic 22-gauge cannula
Number of subjects: 100
Study 7931432 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge cannula with a Quincke bevel
Number of subjects: 100
Study 2906367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg iv dose administered by constant-rate infusion over 30 min
Number of subjects: 12
Study 2906367 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doses of 10 mg, 20 mg, and 40 mg
Number of subjects: 12
Study 2906367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg iv dose, 10 mg oral dose, 20 mg oral dose, 40 mg oral dose
Number of subjects: 12
Study 2906367 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study 30376860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 150
Study 27243414 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge intervention with a specially trained Community Resource Coordinator
Number of subjects: 308
Study 27243414 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 308
Study 27243414 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge intervention
Number of subjects: 308
Study 25535011 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI medication regimen
Number of subjects: 44
Study 25535011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23087419 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg in 0.1 ml injections)
Number of subjects: 30
Study 23087419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 30
Study 19852710 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 71
Study 19852710 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study 18212687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intra-arterial (IA) plus intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Number of subjects: 27
Study 18212687 — intervention group
Group type: COMPARATOR
Intervention: Sole intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Number of subjects: 27
Study 18212687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IA+IM administration of autologous BMC
Number of subjects: 27
Study 15968652 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 23
Study 15968652 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomagnetic Liver Susceptometry (BLS)
Number of subjects: 23
Study 12454805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive-behavioral treatment (CBT) pain management program
Number of subjects: 154
Study 10322244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 12
Study 10322244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 12
Study 10322244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg
Number of subjects: 12
Study 10322244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7492164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 30
Study 7492164 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide plus dexamethasone
Number of subjects: 30
Study 1786051 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (Group A)
Number of subjects: 69
Study 1786051 — intervention group
Group type: COMPARATOR
Intervention: 24 hour bed rest (Group B)
Number of subjects: 69
Study 6461916 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2969 + EE
Number of subjects: 22
Study 6461916 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel + EE
Number of subjects: 22
Study 28984096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg/kg IV and 0.5 mg/kg/h)
Number of subjects: 46
Study 28984096 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 46
Study 26175479 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention designed to reduce substance use, violence and unsafe sex
Number of subjects: 290
Study 25349864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique with spacer
Number of subjects: 90
Study 25349864 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation technique without spacer
Number of subjects: 90
Study 25349864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 23565943 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) intake (150 mg/kg)
Number of subjects: 14
Study 23565943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 mg/kg NaCl)
Number of subjects: 14
Study 21176203 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD prison inmates
Number of subjects: 315
Study 21176203 — intervention group
Group type: COMPARATOR
Intervention: ADHD psychiatric outpatients
Number of subjects: 315
Study 21176203 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 315
Study 18182623 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training (WBVT)
Number of subjects: 20
Study 18182623 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 20
Study 16403616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with standardized mite extracts (D.p. and D.f.)
Number of subjects: 97
Study 16403616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 14606271 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 790
Study 10925649 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglyconate screw (femoral bone block fixation)
Number of subjects: 40
Study 10925649 — intervention group
Group type: COMPARATOR
Intervention: Metal screw (tibial fixation)
Number of subjects: 40
Study 10925649 — intervention group
Group type: COMPARATOR
Intervention: Metal screw (both bone blocks)
Number of subjects: 40
Study 8694295 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg of intrathecal morphine (Group MS)
Number of subjects: 0
Study 8694295 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal saline placebo (Group NS)
Number of subjects: 0
Study 1286050 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP chemotherapy (Etoposide + Epirubicin + Cisplatin)
Number of subjects: 119
Study 1286050 — intervention group
Group type: COMPARATOR
Intervention: FEM chemotherapy (Control)
Number of subjects: 119
Study 1286050 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP chemotherapy
Number of subjects: 119
Study 1286050 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP-FEM comparison
Number of subjects: 119
Study 3890307 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP combination chemotherapy
Number of subjects: 123
Study 3890307 — intervention group
Group type: COMPARATOR
Intervention: CMFVP combination chemotherapy
Number of subjects: 123
Study 3890307 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP combination chemotherapy (as second-line treatment)
Number of subjects: 123
Study 31145885 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of ENG implant
Number of subjects: 100
Study 31145885 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of ENG implant
Number of subjects: 100
Study 31145885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 30307302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products enriched with calcium and vitamin D (250 ml daily)
Number of subjects: 210
Study 26928895 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-question assent process
Number of subjects: 568
Study 26928895 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-question assent process
Number of subjects: 568
Study 26928895 — intervention group
Group type: COMPARATOR
Intervention: No-question assent process (control)
Number of subjects: 568
Study 1481657 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal decongestant in different formulations (varied viscosities)
Number of subjects: 0
Study 22687177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral ultrasound (US)
Number of subjects: 28
Study 22687177 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique (LM)
Number of subjects: 28
Study 20546261 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 75